home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 03/18/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn to Present at Wall Street Reporter's NEXT SUPER STOCK -  Live Stream Event on March 19, 2020

VANCOUVER, Washington, March 18, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, ann...
CYDY - Coronavirus Innovation in Biotech, Hemp / Cannabis, Tech Stocks

Point Roberts, WA and Delta, BC - March 17, 2020 (Investorideas.com Newswire) Investorideas.com , a leading investor news resource covering hemp/ cannabis stocks and coronavirus (COVID-19) stocks issues a snapshot looking at the eruption of innovation in multiple sectors in the face of today's ...

CYDY - CytoDyn advancing mid-stage study of PRO 140 for COVID-19

Base on FDA feedback, CytoDyn ( OTCQB:CYDY   -1% ) has filed a modified IND and protocol with the agency for a Phase 2 clinical trial evaluating lead drug leronlimab (PRO 140) in COVID-19 patients experiencing respiratory complications. More news on: CytoDyn Inc., Healthcare stocks ...

CYDY - CytoDyn Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) and Advises Correction to Press Release Issued on March 12, 2020

VANCOUVER, Washington, March 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - New interim medical chief at CytoDyn

CytoDyn ( OTCQB:CYDY ) has appointed  Jacob P. Lalezari, M.D. as Interim Chief Medical Officer.  Dr. Lalezari is currently leading company's preparations to initiate a COVID-19 clinical trial and will file a modified trial protocol on March 13. More news on: CytoDyn Inc., Health...

CYDY - CytoDyn Appoints Jacob Lalezari, M.D. as Interim Chief Medical Officer

VANCOUVER, Washington, March 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

CYDY - CytoDyn's First mTNBC Patient in Phase 1b/2 is in Remission and Oncologist Ordered Termination of Treatment with Carboplatin (chemotherapy drug) and Remains on Leronlimab Only as Monotherapy; Patient's Testimony about Her Condition After Nearly 6 Months o

VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - A Basket Of Biotechs

It is an exciting time in biotech. It seems like the big challenges are within reach. Cancer, diabetes, infectious diseases. Not everything, not right away. There are still a lot of bald men, for example. And unfortunately, Alzheimer’s seems intractable. But for investors that can mea...

CYDY - CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)

Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn's Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory Illness After Contracting Coronavirus CytoDyn Negotiating ...

CYDY - CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)

Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn's Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory Illness After Contracting Coronavirus CytoDyn Negotiating ...
Previous 10 Next 10